Pharmacy Grand Rounds
Alpha-1 and 1 for All: Evaluating the Role of Midodrine for Vasopressor Discontinuation

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST)

Until future notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

Consistent need for blood pressure support with vasopressors is an incredibly common cause of prolonged ICU stay. Midodrine use in the ICU has steadily increased ever since a few retrospective observational studies discovered a potential reduction in the duration of intravenous vasopressor use. Until recently, all studies regarding the use of midodrine were observational, creating a dire need for a prospective review to fill this research gap. This presentation will review midodrine’s mechanism of action, the current literature regarding its use for vasopressor discontinuation, and ultimately identify its role in therapy in the critical care setting.

At the conclusion of this knowledge-based CE session, participants should be able to:

• Explain the mechanism of action of midodrine
• Review the current evidence for midodrine and its impact on vasopressor discontinuation
• Identify midodrine’s role in therapy for vasopressor discontinuation

Session Announcement

Session Slides

FACULTY INFORMATION

Natalie A. Haddad, PharmD
PGY1  Pharmacy Resident
Mayo Clinic Hospital - Rochester, MN

Natalie received a Doctor of Pharmacy degree from the University of Minnesota in Minneapolis, MN.  She is a current PGY1 Pharmacy Resident at Mayo Clinic Hospital – Rochester with clinical practice interests in critical care and infectious disease.

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Natalie A. Haddad, PharmD
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will be discussed during this presentation, including:
    • Midodrine

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS